Brands
Zydus Lifesciences signs exclusive pact with Myriad Genetics to launch cancer tests in India
Ahmedabad: Zydus Lifesciences Limited., an innovation-led life-sciences company with an international presence, has signed an agreement with Myriad Genetics, a leader in molecular diagnostic testing and precision medicine company. Pursuant to the Agreement, Zydus will be introducing MyRisk® Hereditary Cancer Test, MyChoice® HRD Plus, Homologous Recombination Deficiency (HRD) Test and Prolaris® Prostate Cancer Prognostic Test to patients, clinicians, and healthcare systems across India. With the increasing incidence of cancers globally, the MyRisk® Test can help people safeguard their health and take precautionary steps and lifestyle changes that can minimise the risk of cancer. In patients suffering from prostate and ovarian cancers, the Prolaris® Test and MyChoice® HRD Plus Test, respectively, can help patients understand the disease progression and inform the right treatment path.
Commenting on this, Dr. Sharvil P. Patel, Managing Director, Zydus, said, “This agreement marks a major step in expanding access to precision diagnostic tests for cancer treatment in India. The prostate and ovarian cancer tests help doctors with actionable insights to develop personalised treatment plans, predict disease progression, arrive at treatment decisions and streamline clinical workflows. We are also bringing a test which will help identify hereditary risks in patients and their families. Enabling access to these critical diagnostic tests will benefit patients in getting better clinical outcomes and support their fight against cancer.”
Dr. Sharvil P. Patel, Managing Director, Zydus, went on to say, “Reaffirming Zydus’ deep commitment to patient centricity and precision oncology, this collaboration with Myriad Genetics will strengthen clinician education and diagnostic infrastructure so that patients benefit from earlier, more accurate risk assessment and more confident treatment planning. Together, we aspire to make personalised, evidence-based cancer care accessible to every patient who needs it, helping them navigate their journey with greater clarity and support.”
“This collaboration with Zydus is an important step forward in expanding precision oncology across India,” said Brian Donnelly, Chief Commercial Officer for Myriad Genetics. “Myriad tests aim to empower clinicians with actionable information to assess risk, understand tumour biology, and guide truly personalised care with greater clarity, confidence, and hope as they navigate critical health decisions.”
As part of this agreement, Zydus will exclusively market, create awareness, access and engage clinicians on three of Myriad Genetics’ broadly validated diagnostic platforms, MyRisk® Hereditary Cancer Test, MyChoice® HRD Plus Test for ovarian cancer, and Prolaris® a gene expression Prostate Cancer Prognostic Test.
These tests have been widely adopted in North America, Europe, and major global cancer centres, and will now empower Indian oncologists with cutting-edge genomic decision-support tools.
The MyRisk® Test is a germline multigene panel for individuals with personal or family history suggestive of hereditary cancer. It detects pathogenic variants in high, moderate and emerging-risk genes to estimate lifetime cancer risk and inform personalised prevention strategies.
The MyRisk® Test is a comprehensive panel which analyses 63 clinically significant genes (BRCA1, BRCA2, PALB2, ATM, TP53, MLH1, MSH2, etc.) covering cancer types like, breast, ovarian, lung, pancreatic, colorectal, endometrial, prostate, gastric, and melanoma. It also includes RiskScore® which combines genetic and clinical data to predict 5-year and lifetime breast cancer risk, enabling individualised screening and prevention plans.
About MyRisk®, MyChoice® HRD Plus and Prolaris®
The MyRisk Hereditary Cancer Test with RiskScore evaluates 63 genes associated with hereditary cancer risk to identify genetic changes associated with an increased cancer risk for more than 11 different cancers. When combined with family history and other clinical factors such as breast density, MyRisk with RiskScore provides eligible patients with a five-year and remaining lifetime breast cancer risk assessment individualized to them. The MyRisk® Test can help Indian patients and families identify hereditary cancer risk and plan personalised prevention. This testing would be relevant for: Patients with cancer history (like breast, ovarian, colorectal, endometrial, pancreatic, prostate, melanoma); individuals with strong family history of related or early-onset cancers; or known familial mutation (like BRCA1/2, PALB2, CHEK2, ATM, Lynch genes) and proactive individuals considering risk-reducing surgery, or long-term risk assessment.
The MyChoice® HRD Plus Test is the most comprehensive tumour test for determining HRD status based on the assessment of genomic alterations in genes such as BRCA1 and BRCA2 and Genomic Instability Score (GIS) status using Myriad’s proprietary algorithm. It enables healthcare professionals to identify patients with advanced ovarian cancer who are more likely to respond to treatment with targeted therapies.
The Prolaris® Test is an RNA-based gene expression test that quantifies tumour aggressiveness and provides a patient-specific risk score. The test helps clinicians determine whether active surveillance is appropriate, the need for immediate treatment and a 10-year risk of metastasis and prostate cancer–specific mortality. With prostate cancer incidence rising in India, the Prolaris® Test offers a clinically validated tool for personalised therapy decisions.
Zydus Lifesciences Limited
Zydus Lifesciences Limited is an innovation-led life-sciences company with leadership positions across pharmaceuticals and consumer wellness, supported by an emerging MedTech franchise and a global footprint across the United States, India and other international markets. As of September 30, 2025, the group employs 29,000 people worldwide, including 1,500 scientists engaged in R&D, and is driven by its mission to unlock new possibilities in life sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries.
Myriad Genetics
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs.
Brands
Adobe CEO Shantanu Narayen to step down after 18 years in role
Board begins CEO search as Narayen prepares to move to chair role
SAN JOSE: After nearly two decades at the helm, Adobe’s long-serving chief executive Shantanu Narayen is preparing to pass the baton.
The company announced that Narayen will transition from his role as chief executive officer once a successor is appointed, ending an 18-year run that reshaped Adobe from a boxed software seller into a global cloud and AI powerhouse. He will remain chair of the board following the leadership transition.
Adobe’s board has formed a special committee to oversee the succession process, led by lead independent director Frank Calderoni. The committee will evaluate both internal and external candidates.
“Shantanu’s leadership has been instrumental in Adobe’s transformation and in positioning the company for the AI-driven era,” Calderoni said in a statement. “As we begin the next phase of succession planning, our focus is on identifying the right leader for the company’s next chapter while ensuring a smooth transition.”
In a note to employees, Narayen described the moment not as a farewell but as a pause for reflection after a long journey with the company.
“I love Adobe and the privilege of leading it has been the greatest honour of my career,” he wrote, adding that he will continue to work closely with the board over the coming months to ensure a seamless leadership change.
Tributes from the technology industry quickly followed the announcement. Microsoft chairman and chief executive officer Satya Nadella congratulated Narayen on what he described as a “legendary run” at Adobe.
“Congrats Shantanu, on a legendary run at Adobe! You’ve built one of the most important software companies in the world, and expanded what’s possible for creators, entrepreneurs, and brands everywhere,” Nadella wrote on LinkedIn.
“What has always stood out to me is the empathy you’ve brought to the creative process and the example you’ve set as a leader. Grateful for your friendship, mentorship, and for all you’ve done for Adobe and for our industry.”
Narayen’s career at Adobe spans nearly three decades. He joined the company in 1998 as vice president and rose steadily through the ranks before becoming chief executive officer in December 2007.
During that time, he orchestrated one of the most significant reinventions in the software industry. In 2013, Adobe made the bold decision to abandon traditional boxed software sales and move its flagship creative tools such as Photoshop to a subscription-based Creative Cloud model. The shift initially rattled investors but ultimately transformed Adobe into a predictable recurring revenue business and a case study in digital reinvention.
Narayen also pushed Adobe beyond creative tools into the world of marketing technology and data-driven customer experience, spearheading acquisitions such as Omniture and Marketo. Those moves helped build Adobe’s digital experience division and broaden its reach far beyond designers and photographers.
The numbers tell the story of that transformation. When Narayen took over in 2007, Adobe generated roughly $3 billion in annual revenue. Today the company reports more than $25 billion. Over the same period, its workforce expanded from around 3,000 employees to more than 30,000.
In recent years, Narayen has steered Adobe into the generative AI era with the launch of Adobe Firefly, aiming to keep the company ahead in a rapidly evolving creative technology landscape.
Born in Hyderabad in 1963, Narayen studied electronics and communication engineering at Osmania University before moving to the United States for a master’s degree in computer science from Bowling Green State University. He later earned an MBA from the Haas School of Business at the University of California, Berkeley.
Widely regarded as one of Silicon Valley’s most steady and effective leaders, Narayen has earned multiple honours during his career, including India’s Padma Shri in 2019.
For Adobe, the upcoming leadership change marks the end of a defining chapter. For Narayen, however, the story is far from finished. As he told employees, the company’s next era of creativity, powered by AI and new digital workflows, is only just beginning.
